Hilltop Biosciences Closes New Round of Funding
Hilltop Bio, a veterinary biotech company developing innovative regenerative therapies, is pleased to announce the recent close of its Series A funding round. These funds will be used to continue research and development of its off-the-shelf, room temperature, purified regenerative therapies for horses and companion animals. In addition to R&D, this capital will allow the company to expand operations and its product portfolio to bring innovative new products to our four-legged friends with the goal of accelerating the healing cascade.
Hilltop Bio also filed the first of several INADs with the FDA’s Center for Veterinary Medicine, with the goal of proving the safety and efficacy of these therapies for animals. As a pioneer in the regenerative therapy industry, Hilltop Bio is committed to bringing to veterinarians safe and effective therapies for therapeutic areas.
To learn more about Hilltop Bio, visit their website HilltopBio.com and look for them on Facebook, Instagram, and LinkedIn.
Contact:
Amanda Drobnis
CEO
Hilltop Biosciences
amanda@hilltopbio.com
About Hilltop Biosciences
Hilltop Bio is a veterinary biotech company developing innovative regenerative therapies focused on helping our four-legged friends reduce inflammation from injuries or disease. The company’s strategy is to identify key inflammatory diseases in companion animals and work to provide targeted regenerative therapies to help reduce inflammation and normalize the damaged tissue function. Hilltop Bio has developed a strong pipeline of innovative therapies across many therapeutic classes, alongside cGMP, cGTP manufacturing capabilities, and a developing intellectual property portfolio.
